<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308045">
  <stage>Registered</stage>
  <submitdate>10/06/2009</submitdate>
  <approvaldate>24/06/2009</approvaldate>
  <actrnumber>ACTRN12609000505202</actrnumber>
  <trial_identification>
    <studytitle>A phase 1 study in healthy volunteers to determine the dermatopharmacokinetics of topically applied diclofenac in combination with the novel penetration enhancer Tocopheryl Phosphate Mixture (TPM), compared with Votaren(registered trademark) gel</studytitle>
    <scientifictitle>A phase 1 study in healthy volunteers to determine the dermatopharmacokinetics of topically applied diclofenac in combination with the novel penetration enhancer Tocopheryl Phosphate Mixture (TPM), compared with Votaren (registered trademark) gel</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>N/A</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Muscular or joint pain relief in healthy volunteers currently experiencing no pain</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A gel mixture of Tocopheryl Phosphate Mixture (TPM) and Diclofenac 1% and 2% applied topically to the volar forearms once for a 6 hour period.
Each subject will receive 4 applications of 62.5mg each of each concentration</interventions>
    <comparator>Voltaren Emulgel 1% applied topically to the volar forearms once for a 6 hour period.
Each subject will receive 4 applications of 62.5mg each of Voltaren</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and tolerabilty of TPM/diclofenac assessed via adverse event monitoring and reporting.</outcome>
      <timepoint>Day 1 (dosing day) and Day 7 (follow up post dose)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Dermatopharmacokinetics of TPM/diclofenac assessed by analysis of skin samples obtained by tape stripping</outcome>
      <timepoint>Day 1 pre dose and 1, 2, 4 and 6 hours post dose</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy males and females aged 18 to 55 years inclusive.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Pregnant or breast-feeding, skin conditions preventing gel application, current clinically significant medical conditions, on chronic medications, on medications which may interact with non-steroidal anti-inflamatory drugs</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/07/2009</anticipatedstartdate>
    <actualstartdate>17/10/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate>18/12/2008</actualenddate>
    <samplesize>24</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Phosphagenics Limited</primarysponsorname>
    <primarysponsoraddress>11 Duerdin St
Clayton Victoria 3168</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Phosphagenics Limited</fundingname>
      <fundingaddress>11 Duerdin St
Clayton  Victoria 3168</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is being conducted to see if a TPM/Diclofenac gel mix will penetrate into the skin more, and more quickly, than Voltaren.  It will also assess how safe the gel mix is.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate>9/10/2008</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>30/06/2008</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Paul Gavin</name>
      <address>Phosphagenics Limited
11 Duerdin St
Clayton Victroria 3168</address>
      <phone>+61 3 9565 1119</phone>
      <fax />
      <email>pgavin@phosphagenics.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Paul Gavin</name>
      <address>Phosphagenics Limited
11 Duerdin St
Clayton Victoria 3168</address>
      <phone>+61 3 9565 1119</phone>
      <fax />
      <email>pgavin@phosphagenics.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Alex Veldman</name>
      <address>Phosphagenics Limited 11 Duerdin St Clayton Victoria 3168</address>
      <phone>+61 3 9565 1119</phone>
      <fax />
      <email>pgavin@phosphagenics.com</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>